ALZpath is a passionate and focused group of medical researchers, healthcare professionals, and renowned group of scientific advisors dedicated to transforming the Alzheimer’s disease ecosystem through earlier diagnosis, interventions, and personalized treatment to improve outcomes for people with Alzheimer’s. Launching a novel blood-based biomarker assay for phosphorylated tau 217 (ptau217), ALZpath offers a simple, accessible, timely, and cost-effective approach to diagnosis, which is less invasive than current testing methods. Ptau217 in blood is considered one of the transformative AD diagnostic biomarker, which closely reflects amyloid and tau pathology, the hallmarks of AD, and associates with clinical features of AD.